Who is sponsoring NCT04513314?

NCT04513314 is sponsored by University of Miami.

What condition does NCT04513314 study?

NCT04513314 studies Covid19, Hyperactive Delirium, Pneumonia, Viral.

What drugs are being tested in NCT04513314?

Interventions: Valproate, Quetiapine, Standard of Care.

What is the status of NCT04513314?

NCT04513314 is currently WITHDRAWN.

Last reviewed 2023-03-31 · How we verify

Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium

NCT04513314 PHASE4 WITHDRAWN

The primary purpose of this research is to determine whether Valproate alone, and in combination with Quetiapine, lowers confusion and agitation in persons with severe Corona Virus Disease (COVID)19 pneumonia during weaning from the breathing machine (ventilator). Though Valproate and Quetiapine are often given to persons with severe confusion with agitation, the purpose of this small research study is specifically for: a) persons infected with COVID 2019 on a ventilator whose agitation is not responding to the usual medications (like dexmedetomidine), and b) to reduce the time persons are treated with dexmedetomidine, which requires continuous close monitoring in an ICU.

Details

Lead sponsor	University of Miami
Phase	PHASE4
Status	WITHDRAWN
Start date	Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Covid19
Hyperactive Delirium
Pneumonia, Viral

Interventions

Valproate
Quetiapine
Standard of Care